Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Mattel Inc (MAT) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

Mattel IncTrade
Neurocrine Biosciences IncTrade

Price performance (Past 24H)

Key statistics

Mattel Inc vs Neurocrine Biosciences Inc — how do they compare? Mattel Inc trades at $15.05 (market cap $4.21B), while Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B). The key difference: Neurocrine Biosciences Inc is far larger — about 4× Mattel Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Mattel Inc nearer its low. Which is the better fit depends on your goals.

MATNBIX
Market Cap
$4.21B$16.76B
Sector
Consumer CyclicalHealth
52-Week High
$22.16$185.50
52-Week Low
$13.05$123.10
Enterprise Value
$6.44B$16.78B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Mattel Inc

Mattel (MAT) trades at $14.79, up 2.07% with a bullish technical signal from moving averages. The company reported mixed Q2 2026 results with revenue growth of 10% but an earnings miss due to higher costs. Valuation appears reasonable with P/E of 11.03 and P/S of 0.82, while profitability metrics show strong ROE of 20.5% despite margin pressures from increased advertising expenses.

The stock presents a balanced opportunity with analyst consensus leaning bullish (53% buy ratings) but faces near-term headwinds from cost inflation and discretionary spending pressures. Long-term growth drivers include toy-based entertainment partnerships and digital gaming expansion, though execution risks and market volatility require careful monitoring.

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.

The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Mattel Inc

Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.

Read more on MAT

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX